Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bridge Biotherapeutics raises $10mm in Series A funding

Executive Summary

Bridge Biotherapeutics (inflammatory diseases) raised $10mm in a Series A round from LB Investment and KB Investment. The company was founded in 2015 and is focusing on commercializing compounds developed or discovered by third parties and is currently working on BBT4401, an anti-inflammatory agent discovered by Sungkyunkwan University's professor Park Seok-hee and his research team.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies